Revocation of New York Ruling Letter (NY) R00794, dated September 16,2004; Classification of Everolimus.
Reasoning
Revocation of New York Ruling Letter (NY) R00794, dated September 16,2004; Classification of Everolimus.
Cite this ruling
CBP Ruling 967895 (2941905000): Revocation of New York Ruling Letter (NY) R00794, dated September 16,2004; Classification of Everolimus.
Paste this into a product's override reason when citing this ruling as justification for a classification.
Other rulings for HS6 294190
The tariff classification of Kanamycin B (CAS4696-76-8), imported in bulk form, from China
The tariff classification of Kanamycin A sulfate (CAS-25389-94-0), imported in bulk form, from China
The tariff classification of Mepenzolate Bromide (CAS-76-90-4) imported in bulk form, 6-Methylquinoxaline (CAS-6344-72-5), and Sirolimus (CAS-53123-88-9), imported in bulk form, from France, the Czech Republic and Italy, respectively
The tariff classification of Propofol (CAS-2078-54-8), Pyridostigmine Bromide (CAS-101-26-8), Rifampicin (CAS-13292-46-1), Risperidone (CAS-106266-06-2), Stavudine (CAS-3056-17-5) and Terbinafine Hydrochloride (CAS-78628-80-5), imported in bulk form, from Italy, Spain and Malta
The tariff classification of Ketoconazole (CAS-65277-42-1), 5-Bromo-2-nitropyridine (CAS-39856-50-3) and Rifamycin S (CAS-13553-79-2), imported in bulk form, from Mexico, Austria and India, respectively